Top Pharmaceutical Expiries in 2022: What Patent Cliffs Mean for US & EU Markets

The year 2022 proved to be a defining moment for the pharmaceutical industry as numerous blockbuster medications encountered loss of exclusivity (LOE). This shift allowed the widespread entry of generics and biosimilars, significantly affecting revenue models and compelling major pharmaceutical companies to reassess their strategic approaches, especially in key markets across the US, EU, and Asia-Pacific.

Key Drug Patent Expirations in 2022

Among the most influential drug patent expirations in 2022 were those of Bevacizumab (Avastin) and Lucentis. These critical patent losses opened up the field for biosimilar competitors, with Avastin’s LOE prompting immediate launches across multiple regions. Lucentis' expiration similarly introduced cost-effective alternatives in the retinal treatment segment. Other impactful losses included the expiration of the diabetes medication Januvia, further reshaping therapeutic dynamics.

Global and Regional Strategic Shifts

Insights from US drug patent expiration 2022 reveal significant revenue challenges for drugmakers as brand exclusivity dwindled. In tandem, countries such as Japan, India, Canada, and South Korea adopted their own tactics in response to LOE scenarios. By leveraging internal LOE data systems—like India’s and Europe’s loss of exclusivity databases—many countries encouraged domestic production and promoted cheaper therapeutic alternatives.

Spotlight on Major Patent Expiries

Several pharmaceutical patents that expired in 2022 disrupted therapeutic categories significantly:

• Avastin (oncology): Welcomed biosimilar options post-expiry.

• Cosentyx (autoimmune diseases): Faced mounting competition after LOE.

• Revlimid (blood cancers): Affected treatment regimens due to generic competition.

• Entyvio (inflammatory bowel diseases): Led to a shift in biologics market share.

These cases illustrate the sweeping consequences of patent expirations and the ripple effects across global markets.

Navigating the Future with Informed Strategies

The loss of exclusivity analysis conducted by major markets provided valuable insights into potential opportunities and threats. Many pharmaceutical companies began investing in new drug development or reshaping portfolios to include generics and biosimilars. From introducing new formulations to optimizing pricing models, firms sought to cushion the impact of revenue dips.

Conclusion

The loss of exclusivity pharma strategy in 2022 highlighted how essential patent protection is for sustaining revenues. As major drugs lost exclusivity, companies that adapted quickly—whether through innovation or strategic alliances—were better positioned to maintain their foothold. Continuous tracking of global patent expirations and robust use of LOE data tools are now vital components for pharma competitiveness in a post-2022 landscape.

Latest Reports Offered by Delveinsight:

Parkinson’s Disease Dementia Market | Pars Plantis Market | Pcsk9 Inhibitor Market | Pcsk9 Market | Penicillinbinding Proteins Market | Penile Cancer Market | Persistent Corneal Epithelial Defects Market | Persistent Epithelial Defect Market | Persistent Epithelial Defects Market | Plaque Modification Devices Market | Platinum-resistant Relapsed Ovarian Cancer Market | Polycythemia Vera Market | Pork Tapeworm Infection Market | Post-transplant Lymphoproliferative Disorder Market | Progressive Familial Intrahepatic Cholestasis Market | Prostate Cancer Market | Pseudoxanthoma Elasticum Market | Ranibizumab Biosimilar Insights | Reactive Airway Disease Market | Reactive Airways Disease Market | Recurrent Herpes Labialis Market | Relapsed Chronic Lymphocytic Leukemia Cll Market | Rem Sleep Behavior Disorder Market | Respiratory Syncytial Virus Infections Market | Retinal Neovascularization Market | Rhino Conjunctivitis Market | Rosai-dorfman Disease Market | Sandhoff Disease Market | Scedosporium Infection Market | Secondary Progressive Multiple Sclerosis Spms Market | Severe Hypoglycemia Market | Severe Toxicities In Lymphoma Market | Shigellosis Market | Sick Sinus Syndrome Market | Siderosis Market | Single Ventricle Heart Disease Market | Small Fiber Neuropathy Market

Latest Reports:

https://www.delveinsight.com/sample-request/burn-pain-epidemiology-forecast

https://www.delveinsight.com/sample-request/cardiac-insufficiency-pipeline-insight

https://www.delveinsight.com/sample-request/chemotherapy-induced-hearing-loss-epidemiology-forecast

https://www.delveinsight.com/sample-request/transcranial-doppler-market

https://www.delveinsight.com/sample-request/chemotherapy-induced-diarrhea-market

https://www.delveinsight.com/sample-request/braf-mutant-metastatic-melanoma-market

https://www.delveinsight.com/sample-request/adrenergic-uptake-inhibitor-pipeline-insight

https://www.delveinsight.com/sample-request/liver-cirrhosis-epidemiology-forecast

https://www.delveinsight.com/sample-request/aneurysmal-subarachnoid-hemorrhage-sah-pipeline-insight

https://www.delveinsight.com/sample-request/calciphylaxis-market

About DelveInsight

DelveInsight is a trusted provider of life sciences and pharmaceutical market research and consulting, offering actionable insights that empower organizations to make informed decisions. With a commitment to delivering strategic intelligence, DelveInsight serves as a key partner to global pharmaceutical, biotechnology, and healthcare companies looking to excel in an evolving market landscape.

Contact Us

Kanishk
Email: kkumar@delveinsight.com